So far, nobody has repeated my trial, although there are three more papers using ultrahigh doses of ARBs (Avapro, I believe).

FORBES: Tea Party Boss Prefers Billions In Unnecessary Medicare Spending Rather Than Supporting Small Measure In Obamacare

But Genentech had avoided aiming Herceptin at all patients with breast cancer, instead picking out only a small subset: the 25% of patients whose tumors contained ultrahigh levels of HER-2.

FORBES: Cover Story

In the late 1980s he found that 25% to 30% of breast tumors, including some of the worst cases, had ultrahigh levels of a gene called HER-2 and its protein.

FORBES: Targeting Tumors